ArticleCancer immunology, immunotherapy : CII2022
Evaluation of the efficacy and safety of TAS0313 in adults with recurrent glioblastoma.
Yoshitaka Narita et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this paperpooled itcites it